Efficacy of LD Bio Aspergillus ICT Lateral Flow Assay for Serodiagnosis of Chronic Pulmonary Aspergillosis

Background: The diagnosis of CPA relies on the detection of IgG Aspergillus antibody which is not freely available, especially in resource-poor settings. Point-of-care tests like LDBio Aspergillus ICT lateral flow assay, evaluated in only a few studies, have shown promising results for diagnosis of CPA. However no study has compared the diagnostic performances of LDBio LFA in setting of tuberculosis endemic countries and have compared it with that of IgG Aspergillus. Objectives: This study aimed to evaluate the diagnostic performances of LDBio LFA in CPA and compare it with existing diagnostic algorithm utilising ImmunoCAP IgG Aspergillus. Methods: Serial patients presenting with respiratory symptoms (cough, hemoptysis, fever etc) for > 4 weeks were screened for eligibility. Relevant investigations including direct microscopy and culture of respiratory secretions, IgG Aspergillus, chest imaging etc were done according to existing algorithm. Serum of all patients were tested by LDBio LFA and IgG Aspergillus (ImmunoCAP Asp IgG) and their diagnostic performances were compared. Results: A total of 174 patients were included in the study with ~66.7% patients having past history of tuberculosis. A diagnosis of CPA was made in 74 (42.5%) of patients. The estimated sensitivity and specificity of LDBio LFA was 67.6% (95% CI: 55.7%- 78%) and 81% (95% CI: 71.9%-81%) respectively which increased to 73.3% (95% CI: 60.3%-83.9%) and 83.9% (95% CI: 71.7%-92.4%) respectively in patients with past history of tuberculosis. The sensitivity and specificity of IgG Aspergillus was 82.4% (95% CI: 71.8%-90.3%) and 82% (95% CI: 73.1-89%); 86.7% (95% CI: 75.4%-94.1%) and 80.4% (95% CI: 67.6%-89.8%) in the whole group and those with past history of tuberculosis respectively. Conclusions: LDBio LFA is a point-of-care test with reasonable sensitivity and specificity. However, further tests may have to be done to rule-in or rule-out the diagnosis of CPA in the appropriate setting.

[1]  Chung-Yu Chen,et al.  Investigating Factors of False-Positive Results of Aspergillus Galactomannan Assay: A Case–Control Study in Intensive Care Units , 2021, Frontiers in Pharmacology.

[2]  R. Sarda,et al.  Pulmonary TB and chronic pulmonary aspergillosis. , 2021, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[3]  R. Sarda,et al.  TB and chronic pulmonary aspergillosis: a few relevant points. , 2021, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[4]  S. Sinha,et al.  COVID‐19‐associated subacute invasive pulmonary aspergillosis , 2021, Mycoses.

[5]  S. Vyas,et al.  Unusual case of chronic cavitary pulmonary aspergillosis presenting as spontaneous pneumothorax in an immunocompromised man , 2021, BMJ Case Reports.

[6]  J. Shih,et al.  Establishing Aspergillus-Specific IgG Cut-Off Level for Chronic Pulmonary Aspergillosis Diagnosis: Multicenter Prospective Cohort Study , 2021, Journal of fungi.

[7]  D. Denning,et al.  Performance of LDBio Aspergillus WB and ICT Antibody Detection in Chronic Pulmonary Aspergillosis , 2021, Journal of fungi.

[8]  R. Rathore,et al.  Risk factors for chronic pulmonary aspergillosis in post-TB patients. , 2021, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[9]  R. Adawiyah,et al.  Chronic Pulmonary Aspergillosis in Post Tuberculosis Patients in Indonesia and the Role of LDBio Aspergillus ICT as Part of the Diagnosis Scheme , 2020, Journal of fungi.

[10]  A. Barać,et al.  CPAnet Registry—An International Chronic Pulmonary Aspergillosis Registry , 2020, Journal of fungi.

[11]  B. Kirenga,et al.  Algorithm-aided diagnosis of chronic pulmonary aspergillosis in low- and middle-income countries by use of a lateral flow device , 2019, European Journal of Clinical Microbiology & Infectious Diseases.

[12]  D. Denning,et al.  High-volume culture and quantitative real-rime PCR for the detection of Aspergillus in sputum. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  A. Grande,et al.  Accuracy of serological tests for diagnosis of chronic pulmonary aspergillosis: A systematic review and meta-analysis , 2019, bioRxiv.

[14]  D. Denning,et al.  Evaluation of LDBio Aspergillus ICT Lateral Flow Assay for IgG and IgM Antibody Detection in Chronic Pulmonary Aspergillosis , 2019, Journal of Clinical Microbiology.

[15]  S. Ranque,et al.  Multicenter Evaluation of a Novel Immunochromatographic Test for Anti-aspergillus IgG Detection , 2019, Front. Cell. Infect. Microbiol..

[16]  D. Denning,et al.  Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation , 2019, European Respiratory Journal.

[17]  M. Garg,et al.  Utility of Serum and Bronchoalveolar Lavage Fluid Galactomannan in Diagnosis of Chronic Pulmonary Aspergillosis , 2019, Journal of Clinical Microbiology.

[18]  C. Jude,et al.  Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings , 2018, Emerging infectious diseases.

[19]  M. Garg,et al.  Diagnostic cut‐off of Aspergillus fumigatus‐specific IgG in the diagnosis of chronic pulmonary aspergillosis , 2018, Mycoses.

[20]  D. Denning,et al.  Chronic pulmonary aspergillosis as a cause of smear-negative TB and/or TB treatment failure in Nigerians. , 2017, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[21]  M. Richardson,et al.  Aspergillus serology: Have we arrived yet? , 2017, Medical mycology.

[22]  S. Vyas,et al.  Cavitary Lung Lesions in a Difficult-To-Treat Asthma Patient. , 2016, The Journal of the Association of Physicians of India.

[23]  D. Denning,et al.  Comparison of six Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA). , 2016, The Journal of infection.

[24]  Catherine Beigelman-Aubry,et al.  Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management , 2015, European Respiratory Journal.

[25]  D. Denning,et al.  Estimation of the Burden of Chronic and Allergic Pulmonary Aspergillosis in India , 2014, PloS one.

[26]  D. Denning,et al.  The clinical spectrum of pulmonary aspergillosis , 2014, Thorax.

[27]  K. Hekmat,et al.  Chronic pulmonary aspergillosis , 2014, Mycoses.

[28]  O. Kwon,et al.  Serum galactomannan antigen test for the diagnosis of chronic pulmonary aspergillosis. , 2014, The Journal of infection.

[29]  T. Ng,et al.  Case report: Enteral nutritional supplement as a likely cause of false-positive galactomannan testing , 2013, Medical mycology case reports.

[30]  T. Nishino,et al.  Bronchoalveolar lavage galactomannan for the diagnosis of chronic pulmonary aspergillosis. , 2012, Medical mycology.

[31]  A. Petrie,et al.  Method agreement analysis: a review of correct methodology. , 2010, Theriogenology.

[32]  H. Nunes,et al.  Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. , 2007, Chest.